Although ADI therapy exhibited promising results, several studies in cancer have reported that this therapy inevitably triggers ADI resistance through induction of ASS1 expression and activation of alternate signaling pathways in ASS1-negative cells [17, 18]. Here, ASS1 is linked to cancer.